Professor Chinegwundoh has been actively involved in research for over 25 years, contributing to major national and international clinical studies. His work has helped shape the way prostate cancer, bladder cancer, erectile dysfunction, and urinary conditions are understood and treated.

Prostate & Prostate Cancer

• Transurethral Vaporisation vs. Resection (TVP vs. TURP), 1998–2000 – Participant in a multi-centre NHS Health Technology Assessment study comparing two surgical approaches to benign prostate obstruction.
• TUNA Registry, 2004–2010 – Contributed data to the European Association of Urology Central Registry, as the only UK contributor.
• Prostate Cancer in Ethnic Subgroups (PROCESS), 2003–2007 – Co-recipient of a Department of Health grant. This London and Bristol study, previewed on BBC Online, investigated incidence, presentation, and access to healthcare. Published in 2007.
• Ethnicity and Prostate Cancer in East London, 2003–2006 – Published the first UK data demonstrating increased incidence of prostate cancer in Black men. Abstract in 2003, full paper in December 2006. Ongoing research continues in this area.
• Prognostic Factors in Watchful Waiting, 1999–ongoing – Joint study with Memorial Sloan Kettering (New York) and UK centres, investigating predictors for safely managing men with prostate cancer without radical treatment.
• Intermittent Hormone Therapy with Immediate vs. Deferred Radiation, Barts and The London – Lead clinician and originator of this study. Ten-year follow-up completed in 2012.
• European Study (SEUG9001) into Intermittent Androgen Suppression – Contributor to this international prostate cancer study.
• FE200486 (LHRH Antagonist) Phase 2 Safety and Tolerability Trial, 2003 – Study completed, testing a novel hormonal therapy.
• Dutasteride vs. Placebo to Reduce Risk of Biopsy – Detected Prostate Cancer – International multicentre trial. Recruited men with suspected prostate cancer but negative biopsies to assess whether dutasteride could reduce subsequent risk (estimated at 30%).
• Mitoxantrone, Prednisolone, and YM598 or Placebo in Hormone – Refractory Prostate Cancer, 2003 -Completed recruitment.
• Molecular and Cellular Research
  • Lamins, capsaicin, and granzyme in prostate cancer – supported by the Cancer Research Fund, Barts and The London. Completed 2004. Supervised MD thesis.
  • P1NP vs. Bone Scan in Staging Prostate Cancer, 2002–2004 – assessed whether a blood test could replace bone scans; published results.
  • Gene Therapy for Prostate Cancer, 2005–2007 – collaboration with Institute of Cancer Research. Presented at national/international meetings. Supervised MS thesis, awarded 2008.
  • Role of Gonadotropins in Prostate Cancer, 2006–2007 – supervised MS thesis; published and presented internationally.

Erectile Dysfunction

• Uprima (2mg vs. 3mg) in Erectile Dysfunction, 2003 – Completed study.
• Tadalafil vs. Sildenafil, 2003 – Head-to-head comparison of leading oral treatments; recruitment completed.

Female Urology

• Duloxetine vs. Placebo in Stress Urinary Incontinence, 2004–2005 – Recruited patients into the first international multicentre trial of duloxetine, the first drug licensed for stress incontinence.

Imaging

• Virtual Cystoscopy – Study using CT and 3D reconstruction to image the bladder. Completed and published, with presentation at national meetings.

Bladder Cancer

• Liarazol in Superficial Bladder Cancer, 1998–2000 – Trial completed, exploring novel drug therapy.

Interested in collaborating or learning more about Professor Chinegwundoh’s research work? Contact Professor Chinegwundoh’s office to discuss research, speaking, or partnership opportunities.